Cancer Cell Patents (Class 424/174.1)
-
Publication number: 20140356287Abstract: The invention provides compositions and methods for treating a disease or disorder by lowering the level of PLOD2 in a subject.Type: ApplicationFiled: May 27, 2014Publication date: December 4, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: M. Celeste Simon, T.S. Karin Eisinger
-
Publication number: 20140356364Abstract: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.Type: ApplicationFiled: August 15, 2012Publication date: December 4, 2014Applicant: AMPLIMMUNE, INC.Inventors: Solomon Langermann, Linda Liu, Shannon Marshall
-
Patent number: 8900588Abstract: The present disclosure is directed to methods of treating and preventing breast cancer or recurrence of breast cancer with compositions comprising anti-progastrin antibodies.Type: GrantFiled: January 4, 2011Date of Patent: December 2, 2014Assignees: Les Laboratories Servier, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Jean-François Floch, Leïla Houhou, Françoise Cailler, Dominique Joubert, Frédéric Hollande
-
Publication number: 20140348854Abstract: The invention provides compositions and methods for utilizing human epididymal secretory protein E4 (HE4) in the prevention and treatment of cancer and other human diseases.Type: ApplicationFiled: June 6, 2012Publication date: November 27, 2014Applicant: WOMEN & INFANTS' HOSPITAL OF RHODE ISLANDInventors: Richard G. Moore, Rakesh K. Singh
-
Publication number: 20140348744Abstract: The use of luteinizing hormone receptor (LHR) as a treatment target in cancer is provided. Data demonstrates that LHR plays an important role in androgen synthesis and signaling pathways critical for prostate cancer progression. When LHR is silenced, there is a significant downregulation of androgen receptor (AR) mRNA and protein expression with a subsequent suppression of PSA expression. Data suggesting that the LH-LHR signaling cascade may be an upstream and viable therapeutic target in castration-resistant prostate cancer (CRPC) is presented.Type: ApplicationFiled: May 27, 2014Publication date: November 27, 2014Inventor: Jacek K. Pinski
-
Patent number: 8895001Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: GrantFiled: March 11, 2011Date of Patent: November 25, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Victor Moyo, Gabriela Garcia
-
Publication number: 20140341931Abstract: Disclosed are methods of diagnosing a subject as having a solid tumor or a predisposition to developing a solid tumor. The methods include detecting or quantitating the amount of sCD27 in a serum sample obtained from a subject and comparing that amount of sCD27 with a control value indicative of the basal level of sCD27 present in the serum of a subject that does not have a solid tumor or a predisposition to developing a solid tumor, wherein a reduction of the amount of sCD27 relative to the control value indicates that the subject has the solid tumor or the predisposition to developing the solid tumor. The disclosed methods can be used to monitoring disease progression in a subject or determine a subject's suitability for immunotherapy. Also disclosed are methods of stimulating a subject's immune system by administering a therapeutically effective amount of sCD27 or a functional fragment.Type: ApplicationFiled: May 13, 2014Publication date: November 20, 2014Applicant: THE USA, as represented by the Secretary, Department of Health and Human Services, NationalInventors: Jeffrey Schlom, Jianping Huang
-
Publication number: 20140341894Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.Type: ApplicationFiled: June 5, 2014Publication date: November 20, 2014Inventors: Pingda REN, Yi LIU, Troy Edward WILSON, Liansheng LI, Katrina CHAN, Christian ROMMEL
-
Publication number: 20140335050Abstract: The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-? receptor agonist or an IFN-? receptor agonist, for the treatment of cancer.Type: ApplicationFiled: May 25, 2012Publication date: November 13, 2014Applicants: The General Hospital Corporation, CytoCure LLCInventors: Timothy J. Haggerty, James T. Kurnick, Ian S. Dunn
-
Publication number: 20140335152Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.Type: ApplicationFiled: March 28, 2012Publication date: November 13, 2014Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Yang CHEN, Yan FU, Lin JIA, Guodong CHANG
-
Publication number: 20140335106Abstract: A method of treating cancer by inhibiting expression of ubiquitin associated and SH3 domain containing B (UBASH3B) gene or by inhibiting the activity of UBASH3B protein or a functional variant thereof.Type: ApplicationFiled: September 28, 2012Publication date: November 13, 2014Inventors: Qiang Yu, Shuet Theng Lee
-
Patent number: 8883159Abstract: The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.Type: GrantFiled: August 26, 2010Date of Patent: November 11, 2014Assignee: Hoffmann-La Roche, Inc.Inventors: Birgit Bossenmaier, Georg Fertig, Hans-Willi Krell, Reiner Lammers, Alexander Lifke, Gerhard Niederfellner
-
Publication number: 20140328857Abstract: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.Type: ApplicationFiled: June 3, 2014Publication date: November 6, 2014Applicant: MACROGENICS WEST, INC.Inventors: Jennie P. Mather, Ronghao Li, Zhuangyu Pan, Penelope E. Roberts
-
Publication number: 20140328842Abstract: Methods, reagents and kits are provided for predicting whether an individual suffering from an antibody dependent cell-mediated cytotoxicity (ADCC)-treatable disease is responsive to an antibody maintenance therapy. The methods, reagents, and kits find a number of uses, including, for selecting individuals who will be responsive for treatment with an antibody maintenance therapy, for determining the appropriate maintenance therapy for an individual suffering from an ADCC-treatable disease, for determining the optimal regimen for antibody maintenance therapy, and for treating an individual with an antibody maintenance therapy based on stratification into responsive groups.Type: ApplicationFiled: December 12, 2012Publication date: November 6, 2014Inventor: Vijay Ramakrishnan
-
Publication number: 20140328750Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.Type: ApplicationFiled: July 15, 2014Publication date: November 6, 2014Applicant: MACROGENICS, INC.Inventors: Leslie S. Johnson, Ling Huang, Paul A. Moore, Deryk T. Loo, Francine Z. Chen
-
Publication number: 20140322134Abstract: Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.Type: ApplicationFiled: June 5, 2014Publication date: October 30, 2014Inventors: Philip E. Thorpe, Sophia Ran
-
Publication number: 20140322243Abstract: The present invention provides a method of diagnosing a breast cancer central nervous system (CNS) metastasis in a subject, comprising determining the expression level of at least one biomarker in a subject-derived brain or breast tissue comparing the subject-derived expression level with a normal control level obtained from normal brain or breast cells; and correlating an increase or decrease of the subject-derived expression level as compared to the normal control level to a diagnosis of a breast cancer CNS metastasis. The present invention also provides a method for the treatment of a breast cancer CNS metastasis in a subject comprising administering to the subject an inhibitor of an overexpressed gene associated with CNS metastasis.Type: ApplicationFiled: April 26, 2014Publication date: October 30, 2014Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventor: Bodour Salhia
-
Publication number: 20140322246Abstract: In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fc? receptor.Type: ApplicationFiled: October 4, 2011Publication date: October 30, 2014Applicant: KING'S COLLEGE LONDONInventors: Sophia Karagiannis, Andrew Beavil, Frank Nestle
-
Publication number: 20140322242Abstract: Methods of treating or preventing cancer, or ameliorating a symptom thereof, by administering a muscarinic receptor inhibitor to inhibit cancer metastasis and/or a ? adrenergic receptor inhibitor to inhibit tumor initiation are provided. Also provided are pharmaceutical compositions for treating or preventing cancer comprising a muscarinic receptor inhibitor and/or a ? adrenergic receptor inhibitor.Type: ApplicationFiled: November 24, 2011Publication date: October 30, 2014Applicant: Icahn School of Medicine at Mount SinaiInventors: Paul S. Frenette, Claire Magnon
-
Publication number: 20140322245Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Insulin Receptor protein (IR), and its isoforms IR-A and IR-B, that are particularly advantageous for quantifying the IR protein, IR-A isoform and/or IR-B isoform, directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: July 10, 2014Publication date: October 30, 2014Inventors: David B. KRIZMAN, Wei-Li LIAO, Sheeno THYPARAMBIL, Todd HEMBROUGH
-
Publication number: 20140322244Abstract: The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.Type: ApplicationFiled: May 1, 2014Publication date: October 30, 2014Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATIONInventor: Jennifer D. Wu
-
Publication number: 20140314751Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.Type: ApplicationFiled: April 16, 2014Publication date: October 23, 2014Applicant: SIGNAL PHARMACEUTICALS, LLCInventors: KRISTEN MAE HEGE, RAJESH CHOPRA
-
Publication number: 20140314793Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.Type: ApplicationFiled: April 11, 2014Publication date: October 23, 2014Applicant: BIOINVENT INTERNATIONAL ABInventors: Björn Frendéus, Roland Carlsson, Ingrid Teige, Linda Mårtensson
-
Publication number: 20140314792Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: ApplicationFiled: March 14, 2014Publication date: October 23, 2014Inventors: Roger GOMIS, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
-
Publication number: 20140314752Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of an IMiD® immunomodulatory drug to a patient having a cancer.Type: ApplicationFiled: April 16, 2014Publication date: October 23, 2014Applicant: Signal Pharmaceuticals, LLCInventors: ANTONIA LOPEZ-GIRONA, KRISTEN MAE HEGE, RAJESH CHOPRA
-
Publication number: 20140314675Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.Type: ApplicationFiled: September 7, 2012Publication date: October 23, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140314747Abstract: Methods of predicting whether a cancer will respond to an EGFR inhibitor are provided.Type: ApplicationFiled: March 12, 2014Publication date: October 23, 2014Applicant: Genentech, Inc.Inventors: Geraldine Strasser, Bryan Lo
-
Publication number: 20140308270Abstract: The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of 5% to 20% polyvinylpyrrolidone (PVP) with a molecular weight range of 2000 to 54,000 daltons. The invention further provides a method to minimize inflammation at the injection site during subcutaneous administration of a macromolecule. In further aspects, the invention provides pharmaceutical formulations for subcutaneous administration of a macromolecule, and methods of treating a CD20 positive cancer or an autoimmune disease, comprising administering a humanized anti-CD20 antibody in a pharmaceutical formulation of the invention. The invention further provides an in vitro dialysis method to evaluate the ability of an excipient to reduce aggregation of an antibody or other macromolecule under physiological conditions.Type: ApplicationFiled: November 26, 2013Publication date: October 16, 2014Applicant: Genentech, Inc.Inventors: Brian Lobo, Sabrina Lo, Aditya Wakankar, Yuchang John Wang, Rita L. Wong, Pierre Goldbach, Hanns-Christian Mahler
-
Publication number: 20140308301Abstract: Compositions including an antibody specific for CD44 are provided. These antibodies specifically bind to hematologic malignant cells. Methods to use the CD44 antibodies to target cells expressing CD44 for therapeutic and diagnostic purposes are also provided.Type: ApplicationFiled: October 26, 2012Publication date: October 16, 2014Inventors: Thomas J. Kipps, Suping Zhang, Christina C. Wu
-
Publication number: 20140308294Abstract: The invention relates to polypeptides that block or inhibit the interleukin-1 receptor 1 (IL-1R1), the interaction of IL-1beta with IL-1R1 or the interaction between IL-1R1 and interleukin-1 receptor accessory protein (IL-1RaCP). The invention relates specifically to therapeutic polypeptides that target specifically IL-1R1 present on tumor cells, cancer stem cells, and cancer stem cells which are resistant to chemotherapy or radiotherapy. The invention specifically relates to cancer stem cells (CSC) that express IL-1R1 to which said inhibitors bind. Finally the invention relates to a combination therapy comprising killing tumorigenic differentiating cancer cells by means of standard chemo- or radiotherapy and prior or subsequent to that applying IL-1R1 inhibitors which target specifically CSC and strip the tumor of its capacity to generate cancer cell progeny.Type: ApplicationFiled: April 13, 2012Publication date: October 16, 2014Applicant: MERCK PATENT GMBHInventors: Anita Seshire, Michael Wolf, Robert Tighe, Helen Sabzevari
-
Publication number: 20140308278Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: May 28, 2014Publication date: October 16, 2014Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20140308300Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.Type: ApplicationFiled: May 22, 2014Publication date: October 16, 2014Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Putta, Sudhir Agrawal
-
Publication number: 20140308299Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.Type: ApplicationFiled: April 10, 2014Publication date: October 16, 2014Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
-
Publication number: 20140308283Abstract: This invention relates to a pharmaceutical composition for treatment and/or prevention of pancreatic cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 to 12 or more consecutive amino acid residues.Type: ApplicationFiled: August 3, 2012Publication date: October 16, 2014Applicant: TORAY INDUSTRIES, INC.Inventors: Yoshitaka Minamida, Fumiyoshi Okano, Takanori Saito
-
Publication number: 20140302042Abstract: A set of biomarkers (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use are disclosed.Type: ApplicationFiled: June 29, 2012Publication date: October 9, 2014Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Lynda Chin, Kenneth L. Scott, Papia Ghosh, Kunal Rai, Chengyin Min
-
Publication number: 20140302020Abstract: Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Gilles Bernard TREMBLAY, Mario FILION, Traian SULEA
-
Publication number: 20140302031Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.Type: ApplicationFiled: April 14, 2014Publication date: October 9, 2014Applicant: The Brigham and Women's Hospital, Inc.Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
-
Publication number: 20140294862Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.Type: ApplicationFiled: March 20, 2014Publication date: October 2, 2014Applicant: Celtaxsys, Inc.Inventors: Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
-
Publication number: 20140286861Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: ApplicationFiled: April 23, 2014Publication date: September 25, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20140286967Abstract: The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.Type: ApplicationFiled: June 6, 2014Publication date: September 25, 2014Inventors: Patricia Forgez, Marco Alifano
-
Publication number: 20140271683Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the expression of calreticulin on cancer cells and hematopoietic cells.Type: ApplicationFiled: December 21, 2011Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark P. Chao, Rachel Weissman-Tsukamoto, Siddhartha Jaiswal, Ravindra Majeti, Irving L. Weissman
-
Publication number: 20140271902Abstract: There is presently provided a suspension of immiscible particles in a solution, wherein the particles comprise an agglomeration of a bioactive agent; and a plurality of conjugates of a hyaluronic acid and a flavonoid wherein the particles are on average from about 15 nm to about 300 nm in diameter and wherein the bioactive agent is releasably retained in the particles by the flavonoid. There is also provided a therapeutic formulation comprising such a suspension and methods for using the suspension and therapeutic formulation, including for delivery of a bioactive agent to a cell and for treating a disease, including cancer.Type: ApplicationFiled: May 30, 2014Publication date: September 18, 2014Inventors: Motoichi KURISAWA, Shengyong NG, Joo Eun CHUNG
-
Publication number: 20140271685Abstract: In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: BIN LIU
-
Publication number: 20140271684Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: ApplicationFiled: November 12, 2013Publication date: September 18, 2014Applicants: Medarex, Inc., ADURO GVAX INC.Inventors: Betty LI, Karin JOOSS, Alan J. KORMAN
-
Publication number: 20140271827Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.Type: ApplicationFiled: April 30, 2014Publication date: September 18, 2014Applicant: Massachusetts Institute of TechnologyInventors: Darrell J. Irvine, Jaehyun Moon
-
Publication number: 20140271814Abstract: The present invention is a method and compound for treating cancer and tumors. The invention treats cancer by encapsulating certain cancer fighting drugs in a liposome. Peptides attached to the compound then guide the compound towards its target. During its journey, DSPE-PEG is used to stabilize the compound, to allow more time in the blood stream before losing effectiveness.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Inventor: Shiva Andrali
-
Publication number: 20140271667Abstract: A method for inhibiting tumor cell migration or metastasis of a cancer in a mammalian subject comprises one or more of the steps of administering to a subject a therapeutically effective amount of a composition comprising a molecule that: suppresses focal adhesion kinase (FAK) activity or phosphorylation; suppresses ULK1 kinase activity; suppresses activation or signaling of the mTORC1 (Ser757) pathway; activates AMPK; activates FIP200; or activates LKB1, in a cancer cell. Still another method of inhibiting tumor cell migration involves inhibiting phosphorylation of ULK1 on Ser757 in subjects with lung cancer. Suppressing activation or signaling of the mTORC1 (Ser757) pathway in subjects is in one aspect useful in treating lung cancer.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: The Wistar Institute of Anatomy and BiologyInventors: Dario C. Altieri, Young Chan Chae
-
Patent number: 8834878Abstract: A method for the treatment of cancer is provided wherein a cancer recognition (CARE) antigen or CARE antibody is administered to a patient. Administration of the CARE antigen or antibody will induce an immune or promote a response of IgM CARE antibodies which will bind to CARE antigen bound to cancer cells, inducing an immune response to destroy the cancer cells. Subsequent to said treatment, ELISA assays may be used to detect levels of said CARE antigen to monitor the efficacy of the treatment, and to govern the further administration of CARE antigens.Type: GrantFiled: June 6, 2007Date of Patent: September 16, 2014Inventor: Jerry T. Thornthwaite
-
Patent number: 8834875Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.Type: GrantFiled: January 13, 2011Date of Patent: September 16, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventor: Edward Thein Htun Van Der Horst
-
Publication number: 20140255431Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.Type: ApplicationFiled: January 24, 2014Publication date: September 11, 2014Inventors: Ravindra Majeti, Irving L. Weissman